NCT06195189View on ClinicalTrials.gov

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

February 1, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Sunvozertinib

Sunvozertinib 200mg Quaquedie (QD)

DRUG

Chemotherapy

Pemetrexed +platinum

Trial Locations (1)

610044

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER